Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2009;53:77-82
Published online before print December 1, 2008, doi: 10.1161/HYPERTENSIONAHA.108.120725
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
53/1/77    most recent
HYPERTENSIONAHA.108.120725v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sanada, F.
Right arrow Articles by Morishita, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sanada, F.
Right arrow Articles by Morishita, R.
Related Collections
Right arrow Angiogenesis
Right arrow Risk Factors
Right arrow Growth factors/cytokines
Right arrow Peripheral vascular disease
Right arrow Gene therapy
Right arrow Oxidant stress
Right arrow Mechanism of atherosclerosis/growth factors

(Hypertension. 2009;53:77.)
© 2009 American Heart Association, Inc.


Original Articles

Hepatocyte Growth Factor, but not Vascular Endothelial Growth Factor, Attenuates Angiotensin II–Induced Endothelial Progenitor Cell Senescence

Fumihiro Sanada; Yoshiaki Taniyama; Junya Azuma; Kazuma Iekushi; Norio Dosaka; Toyohiko Yokoi; Nobutaka Koibuchi; Hiroshi Kusunoki; Yoshifusa Aizawa; Ryuichi Morishita

From the Departments of Clinical Gene Therapy (F.S., Y.T., J.A., K.I., N.D., H.K., R.M.) and Geriatric Medicine and Nephrology (Y.T., J.A., K.I., N.D., T.Y., H.K.), Osaka University Graduate School of Medicine, Osaka; Department of Cardiology (F.S., Y.A.), Niigata University Graduate School of Medicine, Niigata; and the Department of Advanced Clinical Science and Therapeutics (N.K.), Graduate School of Medicine, University of Tokyo, Tokyo, Japan.

Correspondence to Ryuichi Morishita, Department of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Osaka, Japan. E-mail morishit{at}cgt.med.osaka-u.ac.jp

Although both hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) are potent angiogenic growth factors in animal models of ischemia, their characteristics are not the same in animal experiments and clinical trials. To elucidate the discrepancy between HGF and VEGF, we compared the effects of HGF and VEGF on endothelial progenitor cells under angiotensin II stimulation, which is a well-known risk factor for atherosclerosis. Here, we demonstrated that HGF, but not VEGF, attenuated angiotensin II–induced senescence of endothelial progenitor cells through a reduction of oxidative stress by inhibition of the phosphatidylinositol-3,4,5-triphosphate/rac1 pathway. Potent induction of neovascularization of endothelial progenitor cells by HGF, but not VEGF, under angiotensin II was also confirmed by in vivo experiments using several models, including HGF transgenic mice.


Key Words: HGF • VEGF • angiotensin II • EPC • senescence • oxidative stress




This article has been cited by other articles:


Home page
Circ. Res.Home page
F. Sanada, Y. Taniyama, K. Iekushi, J. Azuma, K. Okayama, H. Kusunoki, N. Koibuchi, T. Doi, Y. Aizawa, and R. Morishita
Negative Action of Hepatocyte Growth Factor/c-Met System on Angiotensin II Signaling via Ligand-Dependent Epithelial Growth Factor Receptor Degradation Mechanism in Vascular Smooth Muscle Cells
Circ. Res., September 25, 2009; 105(7): 667 - 675.
[Abstract] [Full Text] [PDF]